METTL3 could enhance the m6A methylation of pri-miR-221-3p, thereby increasing the expression of miR-221-3p and increase the drug resistance of breast cancer cells through the miR-221-3p/HIPK2/Che-1 axis (134). Here, METTL3 is linked to breast carcinoma.